Fibroblast growth factor 9 (FGF9) plays a critical role in patients with colon cancer with resistance to epidermal growth factor receptor (EGFR)-targeted therapy, and combination therapy with anti-EGFR inhibitor may reverse drug resistance [21]. Here, FGF9 is linked to colonic neoplasm.